Zenotech Laboratories share news, announcements and annual reports
BSE: 532039Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 29 Oct 2026. Previous close ₹37.80.
29 Oct: open ₹38.06, high ₹39.20, low ₹36.92
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹232 Cr2,190th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.51
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −4.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −8.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 19,861
Zenotech Laboratories share news and announcements
496 announcements, routine notices left out, newest first. Page 8 of 10.
May 2017
13 May · Board Meeting On Saturday, May 20, 2017
Apr 2017
21 Apr · Zenotech Laboratories Limited - Compliance Certificate For The Half Year Ended March 31, 2017
14 Apr · Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
13 Apr · Compliance Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2017
10 Apr · Shareholding for the Period Ended March 31, 2017
Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click ....7 Apr · Statement Of Investor Complaints For The Quarter Ended March 31, 2017
Mar 2017
23 Mar · Updates
Feb 2017
Jan 2017
10 Jan · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
10 Jan · Shareholding for the Period Ended December 31, 2016
Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click ....
Dec 2016
30 Dec · Board meeting
Nov 2016
Oct 2016
9 Oct · Shareholding for the Period Ended September 30, 2016
Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click ....8 Oct · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Sep 2016
Aug 2016
8 Aug · Limited Review Report for June 30, 2016
Jul 2016
7 Jul · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
6 Jul · Shareholding for the Period Ended June 30, 2016
Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click ....
Jun 2016
30 Jun · Standalone Statement on Impact of Audit Qualifications for the period ended March 31, 2016
May 2016
21 May · Board meeting
Board of Directors of the Company at its meeting held on May 21, 2016, whin commenced and concluded at 4.10 p.m., inter alia, has considered ....9 May · The outcome of arbitration proceeding with certain former shareholders of Ranbaxy
Apr 2016
20 Apr · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
20 Apr · Shareholding for the Period Ended March 31, 2016
Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click ....
Mar 2016
23 Mar · Authorised KMPs to determine materiality of events/information
17 Mar · Shareholding for the Period Ended December 31, 2015
Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click ....9 Mar · Board meeting
Board of Directors of the Company at its meeting held on March 09, 2016 has appointed, Mr. Abdul Gafoor as Compliance Officer of the ....
Feb 2016
16 Feb · Shareholding for the Period Ended December 31, 2015
Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click ....
Jan 2016
21 Jan · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Nov 2015
16 Nov · Management
Mr. Chinmoy Patnaik, Company Secretary and Compliance officer of the Company had resigned and relieved from his duties at the closing hours ....
Oct 2015
21 Oct · Shareholding Pattern for September 30, 2015
Sep 2015
22 Sep · Registration as a “Sick Industrial Company" with Board for Industrial and Financial Reconstruction (BIFR)
Pursuant to the Reference filed by the Company under the provisions of Section 15 (1) of Sick industrial Companies (Special Provisions) Act, ....